Analyst Price Targets — AXGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 29, 2026 1:17 pm | — | Raymond James | $48.00 | $41.79 | TheFly | AxoGen price target raised to $48 from $41 at Raymond James |
| April 29, 2026 11:25 am | Caitlin Roberts | Canaccord Genuity | $50.00 | $41.99 | TheFly | AxoGen price target raised to $50 from $45 at Canaccord |
| April 29, 2026 10:06 am | — | H.C. Wainwright | $50.00 | $41.99 | TheFly | AxoGen price target raised to $50 from $39 at H.C. Wainwright |
| April 24, 2026 11:11 am | — | Canaccord Genuity | $45.00 | $37.41 | TheFly | AxoGen price target raised to $45 from $40 at Canaccord |
| February 23, 2026 2:43 pm | Jayson Bedford | Raymond James | $41.00 | $35.00 | TheFly | AxoGen price target raised to $41 from $36 at Raymond James |
| February 19, 2026 10:50 am | — | Wells Fargo | $40.00 | $35.25 | TheFly | AxoGen initiated with an Overweight at Wells Fargo |
| December 5, 2025 4:01 pm | — | H.C. Wainwright | $39.00 | $33.70 | TheFly | AxoGen price target raised to $39 from $26 at H.C. Wainwright |
| December 5, 2025 11:41 am | — | Canaccord Genuity | $37.00 | $32.86 | TheFly | AxoGen price target raised to $37 from $27 at Canaccord |
| December 4, 2025 3:02 pm | Jayson Bedford | Raymond James | $36.00 | $33.19 | StreetInsider | AxoGen, Inc. (AXGN) PT Raised to $36 at Raymond James |
| December 4, 2025 1:47 pm | Frank Takkinen | Lake Street | $40.00 | $32.10 | TheFly | AxoGen price target raised to $40 from $30 at Lake Street |
Latest News for AXGN
ALACHUA, Fla. and TAMPA, Fla., July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026. Axogen management will host an investment-community conference call and webcast at…
ALACHUA, Fla. and TAMPA, Fla. , July 15, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced that it will release financial results for the second quarter of 2026 on Wednesday, July 29, 2026.
AxoGen, Stock Of the Day, is flashing a buy signal. Ten out of 10 analysts are bullish about AxoGen after strong earnings and raised 2026 guidance.
AxoGen NASDAQ: AXGN President and CEO Michael Dale said the company's growth strategy remains centered on developing the market for peripheral nerve repair, while recent reimbursement wins are expected to be positive but have not yet been quantified.
Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AXGN.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.